1,222
Views
4
CrossRef citations to date
0
Altmetric
Hematology

Value of innovation for hematologic malignancies

Pages 487-489 | Accepted 15 Dec 2015, Published online: 11 Jan 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

M. Sakil Syeed, Nabin Poudel, Surachat Ngorsuraches, Jose Diaz & Nathorn Chaiyakunapruk. (2022) Measurement and valuation of the attributes of innovation of healthcare technologies: a systematic review. Journal of Medical Economics 25:1, pages 1176-1184.
Read now
M. Sakil Syeed, Nabin Poudel, Surachat Ngorsuraches, Sajesh K. Veettil & Nathorn Chaiyakunapruk. (2022) Characterizing attributes of innovation of technologies for healthcare: a systematic review. Journal of Medical Economics 25:1, pages 1158-1166.
Read now
Monia Marchetti, Luca Albertin, Giulia Limberti & Manuela Canicattì. (2022) Pharmacoeconomic considerations for acute myeloid leukemia pharmacotherapy. Expert Opinion on Pharmacotherapy 23:2, pages 263-272.
Read now
Monia Marchetti. (2017) Cost-effectiveness of kinase inhibitors for hematologic malignancies: a systematic and critical review. Expert Review of Pharmacoeconomics & Outcomes Research 17:5, pages 469-480.
Read now

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.